Rankings
▼
Calendar
AUPH Q3 2024 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena
AUPH
Aurinia Pharmaceuticals Inc.
$2B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$68M
+24.3% YoY
Gross Profit
$62M
91.1% margin
Operating Income
$12M
17.3% margin
Net Income
$14M
21.2% margin
EPS (Diluted)
$0.10
QoQ Revenue Growth
+18.5%
Cash Flow
Operating Cash Flow
$17M
Free Cash Flow
$17M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$549M
Total Liabilities
$161M
Stockholders' Equity
$388M
Cash & Equivalents
$37M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$68M
$55M
+24.3%
Gross Profit
$62M
$48M
+29.3%
Operating Income
$12M
-$16M
+172.2%
Net Income
$14M
-$13M
+206.7%
Revenue Segments
Product
$56M
82%
License, Royalty and Collaboration Revenue
$12M
18%
← FY 2024
All Quarters
Q4 2024 →